Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Change in Inventory: 2018-2025

Historic Change in Inventory for Coherus Oncology (CHRS) over the last 7 years, with Sep 2025 value amounting to -$2.5 million.

  • Coherus Oncology's Change in Inventory fell 135.72% to -$2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.4 million, marking a year-over-year decrease of 39.81%. This contributed to the annual value of $32.0 million for FY2024, which is 31.63% down from last year.
  • As of Q3 2025, Coherus Oncology's Change in Inventory stood at -$2.5 million, which was up 34.22% from -$3.8 million recorded in Q2 2025.
  • In the past 5 years, Coherus Oncology's Change in Inventory registered a high of $23.4 million during Q3 2022, and its lowest value of -$7.5 million during Q2 2021.
  • Moreover, its 3-year median value for Change in Inventory was $7.1 million (2024), whereas its average is $8.6 million.
  • As far as peak fluctuations go, Coherus Oncology's Change in Inventory plummeted by 241.08% in 2021, and later surged by 443.63% in 2022.
  • Quarterly analysis of 5 years shows Coherus Oncology's Change in Inventory stood at $9.2 million in 2021, then grew by 6.56% to $9.8 million in 2022, then grew by 20.44% to $11.8 million in 2023, then tumbled by 45.28% to $6.5 million in 2024, then plummeted by 135.72% to -$2.5 million in 2025.
  • Its last three reported values are -$2.5 million in Q3 2025, -$3.8 million for Q2 2025, and $22.2 million during Q1 2025.